TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05454943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized TRE Protocol
Description: A standardized 16:8 TRE protocol with an 11 am to 7 pm eating window.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized TRE Protocol
Description: A standardized 16:8 TRE protocol with an 11 am to 7 pm eating window.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized TRE Protocol
Description: A personalized TRE protocol following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized TRE Protocol
Description: A personalized TRE protocol following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Support for TRE
Description: External support (from study staff) that includes consultation with a registered dietitian and ongoing tailored feedback via support calls at weeks 1, 3, 6, and 12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Support for TRE
Description: External support (from study staff) that includes consultation with a registered dietitian and ongoing tailored feedback via support calls at weeks 1, 3, 6, and 12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support for TRE
Description: Matched pairs will meet by phone/video at weeks 1, 3, 6, and 12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support for TRE
Description: Matched pairs will meet by phone/video at weeks 1, 3, 6, and 12.
Study: NCT04818281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 VLP Vaccine
Description: VLP adjuvanted vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 VLP Vaccine
Description: VLP adjuvanted vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl
Study: NCT05770947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT) is a psychological treatment or talk therapy that integrates how people think, feel, and behave to create new behavior patterns that improve thinking processes and reduce distress.
Study: NCT04701645

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Microdevice
Description: Placement of 1 to 6 implantable microdevices with multiple miniature drug reservoirs into a tumor mass 24 +/- 8 hours prior to surgery. Drugs will be released over 24 (+/- 8) hours while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice will harbor up to 20 drugs and drug combinations relevant to the treatment of ovarian cancer.~* Each drug or drug combination will be released from a single, separate reservoir. At least two reservoirs will harbor a drug vehicle only.~* Drugs will include all or a subset of the following: Cisplatin, Carboplatin, Paclitaxel, Doxorubicin or pegylated liposomal doxorubicin (PLD), Cyclophosphamide, Etoposide, Gemcitabine, Ifosfamide, Pemetrexed, Topotecan, Vinorelbine, Olaparib, Niraparib, Rucaparib, Carboplatin + paclitaxel (combination), Carboplatin + doxorubicin (combination),Carboplatin + gemcitabine (combination)
Study: NCT05770947

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Mindfulness is a psychological treatment or talk therapy that practices different coping skills to improve thinking processes and reduce distress.
Study: NCT05947370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine Chloride
Description: Traditional Chinese medicine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Berberine Chloride
Description: Traditional Chinese medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT05670366

Intervention type: DEVICE
Group type: OTHER
Intervention: Activity tracker and chest strap
Description: During the study, the participants will be asked to wear a commercially-available activity tracker during day and night, and a chest strap during sport activities to collect data on physical activity (type, intensity and duration of activity).

Intervention type: DEVICE
Group type: OTHER
Intervention: Diary app
Description: During the study, the participants will be asked to log the ingestion of carbohydrates, periods and type of physical activity, feelings (e.g. sick, stress, ...) in a diary app.
Study: NCT05869422

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron
Description: 90 ± 5 days of daily oral iron supplementation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 90 ± 5 days of daily oral placebo intake.
Study: NCT04644744

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermic oxygenated perfusion (HOPE)
Description: HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated perfusion (HOPE)
Description: HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Normothermic machine perfusion (NMP)
Description: End-ischemic NMP will be continued throughout the recipient hepatectomy and until the transplanting team is ready to implant the liver. The minimum protocol-stipulated NMP duration is 4 hours, the time needed for ATP repletion in animal studies. Total NMP preservation time will be according to the official recommendations of the manufacturer (4-24 hours) and at the discretion of the local transplant centre. The liver allograft will be disconnected from the OrganOx metra® device immediately prior to transplantation and flushed with three litres of HTK via the hepatic artery and the portal vein.
Study: NCT06633770

Intervention type: DIAGNOSTIC_TEST
Intervention: proclcitonin and presepsin
Description: All included patients will be subjected to:~* laboratory investigations~  * Complete Blood Count (CBC),~ * Liver Function Test(LFT) ( ALT,AST, Billirubin, total protein and albumin)~ * Kidney function test (KFT) ( Urea and creatinine)~ * Random Blood Glucose (RBG).~ * Erythrocyte Sedimentation Rate(ESR )~ * Urine analysis -A special investigations include (blood culture, C Reactive protein (CRP), proclcitonin and presepsin).

Intervention type: DIAGNOSTIC_TEST
Intervention: proclcitonin and presepsin
Description: All included patients will be subjected to:~* laboratory investigations~  * Complete Blood Count (CBC),~ * Liver Function Test(LFT) ( ALT,AST, Billirubin, total protein and albumin)~ * Kidney function test (KFT) ( Urea and creatinine)~ * Random Blood Glucose (RBG).~ * Erythrocyte Sedimentation Rate(ESR )~ * Urine analysis -A special investigations include (blood culture, C Reactive protein (CRP), proclcitonin and presepsin).
Study: NCT06173271

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multi-intervention program and protein foods supplementation
Description: This study aimed to investigate the effects of a multi-intervention program (protein-rich food supplement, nutrition education, and exercise) on reducing the risk of sarcopenia.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: multi-intervention program and protein foods supplementation
Description: This study aimed to investigate the effects of a multi-intervention program (protein-rich food supplement, nutrition education, and exercise) on reducing the risk of sarcopenia.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multi-intervention program and protein foods supplementation
Description: This study aimed to investigate the effects of a multi-intervention program (protein-rich food supplement, nutrition education, and exercise) on reducing the risk of sarcopenia.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multi-intervention program and protein foods supplementation
Description: This study aimed to investigate the effects of a multi-intervention program (protein-rich food supplement, nutrition education, and exercise) on reducing the risk of sarcopenia.
Study: NCT06233773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio Taping

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio Taping

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Lymph Drainage
Description: Manual Lymph Drainage Group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Lymph Drainage
Description: Manual Lymph Drainage Group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control Group
Study: NCT06113302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Given by SC or (Injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Given by SC or (Injection)
Study: NCT06206629

Intervention type: DIAGNOSTIC_TEST
Intervention: blink reflex evaluation
Description: A blink reflex evaluation will be performed in all subjects
Study: NCT04644744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Description: End-ischemic NMP will be continued throughout the recipient hepatectomy and until the transplanting team is ready to implant the liver. The minimum protocol-stipulated NMP duration is 4 hours, the time needed for ATP repletion in animal studies. Total NMP preservation time will be according to the official recommendations of the manufacturer (4-24 hours) and at the discretion of the local transplant centre. The liver allograft will be disconnected from the OrganOx metra® device immediately prior to transplantation and flushed with three litres of HTK via the hepatic artery and the portal vein.
Study: NCT05145855

Intervention type: OTHER
Intervention: Patient-tailored multimodal neglect rehabilitation
Description: Patient-tailored neglect rehabilitation program which comprises 30-45 minutes of sessions, five times per week includes a combination of reading, copying, and representational drawing tasks with visual or verbal cueing, visual scanning, mirror therapy, and allocation of attention to the neglected side using multimodal stimulus in daily activities.

Intervention type: OTHER
Intervention: Patient-tailored multimodal neglect rehabilitation
Description: Patient-tailored neglect rehabilitation program which comprises 30-45 minutes of sessions, five times per week includes a combination of reading, copying, and representational drawing tasks with visual or verbal cueing, visual scanning, mirror therapy, and allocation of attention to the neglected side using multimodal stimulus in daily activities.
Study: NCT04947631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKF-313
Description: Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: Dutasteride 0.5 mg once daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil 5 mg once daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DKF-313 placebo
Description: Once daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DKF-313 placebo
Description: Once daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride placebo
Description: Once daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride placebo
Description: Once daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil placebo
Description: Once daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil placebo
Description: Once daily for 48 weeks
Study: NCT04859244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-441524
Description: 750 mg administered as a solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-441524
Description: 750 mg administered as a solution
Study: NCT05744726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-PRF
Description: 0.5 to 1g of Advance Platelet-Rich Fibrin (A-PRF) clot for each dental socket.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Bone-wax
Description: 0.5 to 1g of Bone-wax for each dental socket
Study: NCT06206629

Intervention type: DIAGNOSTIC_TEST
Intervention: blink reflex evaluation
Description: A blink reflex evaluation will be performed in all subjects

Intervention type: DIAGNOSTIC_TEST
Intervention: blink reflex evaluation
Description: A blink reflex evaluation will be performed in all subjects
Study: NCT06348615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-cellulite cream-gel Medical Device (DEFBODY)
Description: one bottle of 400 ml, twice a day
Study: NCT05335564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General information about depression
Description: Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants will be shown parts of the website regarding general information about depression.
Study: NCT05770895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-2829
Description: Administered intramuscularly
Study: NCT05618041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T Autologous T cell injection
Description: Biological: CAR-T; Drug: Cyclophosphamide,Fludarabine；Procedure: Leukapheresis
Study: NCT05851781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide tablet
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study: NCT05398601

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MOBILIZATION with MOVEMENT
Description: They would be receiving conventional treatment as follow:~TENS (Transcutaneous electrical nerve stimulation) applied asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold - 10 mins Hot Pack - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive MWM techniques for Knee~1. Medial glide~2. Medial+ Internal rotation glide~3. Lateral Glide+ Internal Rotation glide~4. Anterior glide~5. Posterior glide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periosteal electrical dry needling
Description: They would be receiving conventional treatment as follow:~TENS (asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold) - 10 mins HOT PACK - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive periosteal electrical dry needling 4 point technique for Knee~Four sterile, single-use 30-gauge dry needles would be inserted into the following locations of the symptomatic knee(s) until they touch bone:~1. Medial femoral condyle~2. Lateral femoral condyle~3. Flare of the tibia~4. Head of the fibula Needles would be stimulated with 100 Hz for 30 minutes. The intensity of the stimulus would be adjusted so that it would be clearly felt but would not cause discomfort. The stimulus intensity would be adjusted periodically so that it is perceptible for the entire 30 minutes of PST.
Study: NCT05770895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-2829
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-2829
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-2829
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-2829
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-2829
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-6779
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-6779
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-6779
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-6779
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-6779
Description: Administered intramuscularly
Study: NCT05060380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Progressive muscle resistive exercise will be performed by the experimental group only. Control group will maintain their normal level of daily activity.
Study: NCT03345654

Intervention type: OTHER
Intervention: Hearing Aids
Description: The signal processing of newly fit hearing aids will be evaluated for acceptability based on the toolset, which takes additional patient information beyond hearing threshold (like cognition) to determine the optimal hearing aid signal processing strategies.
Study: NCT05607498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMB07
Description: EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMB07
Description: EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
Study: NCT05630222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: Ibuprofen from Caspian Taamin Company

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine Sulfate from Darupakhsh Company

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg plus Acetaminophen 1000 mg
Description: Both from Caspian Taamin Company
Study: NCT05770895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-6779
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-6779
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-2829
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-2829
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-2829
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-2829
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-2829
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-2829
Description: Administered intramuscularly
Study: NCT05770895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-2829
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-6779
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-6779
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-6779
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-6779
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-6779
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-6779
Description: Administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for GS-6779
Description: Administered intramuscularly
Study: NCT06581055

Intervention type: DRUG
Intervention: Luspatercept
Description: As per COMMANDS Trial (NCT03682536) study protocol

Intervention type: DRUG
Intervention: Epoetin Alfa
Description: As per COMMANDS Trial (NCT03682536) study protocol
Study: NCT06201156

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metered Dose Inhaler With Spacer Device
Description: Bronchodilator Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler With Spacer Device
Description: Bronchodilator Therapy